359 related articles for article (PubMed ID: 3260814)
21. The activity of two immunotoxins composed of monoclonal antibody MoAb-16 and A-chain of ricin (MoAb-16-RTA) or A-chain of mistletoe lectin I (MoAb-16-MLIA).
Paprocka M; Wiedłocha A; Walzel H; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1992; 40(3-4):223-7. PubMed ID: 1300987
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the cytotoxic potency of T101 Fab, F(ab')2 and whole IgG immunotoxins.
Derocq JM; Casellas P; Laurent G; Ravel S; Vidal H; Jansen F
J Immunol; 1988 Oct; 141(8):2837-43. PubMed ID: 3262669
[TBL] [Abstract][Full Text] [Related]
23. The effect of antibody valency and lysosomotropic amines on the synergy between ricin A chain- and ricin B chain-containing immunotoxins.
Fulton RJ; Uhr JW; Vitetta ES
J Immunol; 1986 Apr; 136(8):3103-9. PubMed ID: 3958490
[TBL] [Abstract][Full Text] [Related]
24. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
Fulton RJ; Uhr JW; Vitetta ES
Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
[TBL] [Abstract][Full Text] [Related]
25. Human melanoma cell lines showing striking inherent differences in sensitivity to immunotoxins containing holotoxins.
Godal A; Fodstad O; Morgan AC; Pihl A
J Natl Cancer Inst; 1986 Dec; 77(6):1247-53. PubMed ID: 3491924
[TBL] [Abstract][Full Text] [Related]
26. Parameters affecting tumor-specific delivery of anti-CD5 antibody-ricin A chain immunotoxins in vivo.
Rostaing-Capaillon O; Casellas P
Cancer Res; 1990 May; 50(10):2909-16. PubMed ID: 1692250
[TBL] [Abstract][Full Text] [Related]
27. Antitumor activity of L6-ricin immunotoxin against the H2981-T3 lung adenocarcinoma cell line in vitro and in vivo.
Schmidberger H; King L; Lasky LC; Vallera DA
Cancer Res; 1990 Jun; 50(11):3249-56. PubMed ID: 1692258
[TBL] [Abstract][Full Text] [Related]
28. Toxicity of ligand and antibody-directed ricin A-chain conjugates recognizing the epidermal growth factor receptor.
Vollmar AM; Banker DE; Mendelsohn J; Herschman HR
J Cell Physiol; 1987 Jun; 131(3):418-25. PubMed ID: 3496342
[TBL] [Abstract][Full Text] [Related]
29. Assessment of ligand effects in intracellular trafficking of ricin A chain using anti-ricin hybridomas.
Kornfeld SB; Leonard JE; Mullen MD; Taetle R
Cancer Res; 1991 Mar; 51(6):1689-93. PubMed ID: 1998959
[TBL] [Abstract][Full Text] [Related]
30. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody.
Blakey DC; Watson GJ; Knowles PP; Thorpe PE
Cancer Res; 1987 Feb; 47(4):947-52. PubMed ID: 3492271
[TBL] [Abstract][Full Text] [Related]
31. Immunotoxins to a human melanoma-associated antigen: comparison of gelonin with ricin and other A chain conjugates.
Sivam G; Pearson JW; Bohn W; Oldham RK; Sadoff JC; Morgan AC
Cancer Res; 1987 Jun; 47(12):3169-73. PubMed ID: 3495329
[TBL] [Abstract][Full Text] [Related]
32. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.
Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Blakey DC; Newell DR
Cancer Res; 1988 Nov; 48(22):6396-403. PubMed ID: 3263186
[TBL] [Abstract][Full Text] [Related]
33. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
34. Blockade of the galactose-binding sites of ricin by its linkage to antibody. Specific cytotoxic effects of the conjugates.
Thorpe PE; Ross WC; Brown AN; Myers CD; Cumber AJ; Foxwell BM; Forrester JT
Eur J Biochem; 1984 Apr; 140(1):63-71. PubMed ID: 6608447
[TBL] [Abstract][Full Text] [Related]
35. Kinetics of protein synthesis inactivation in human T-lymphocytes by selective monoclonal antibody-ricin conjugates.
Leonard JE; Wang QC; Kaplan NO; Royston I
Cancer Res; 1985 Nov; 45(11 Pt 1):5263-9. PubMed ID: 3876881
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfreundschuh M; Diehl V; Thorpe P
Cancer Res; 1990 Jan; 50(1):84-8. PubMed ID: 2152774
[TBL] [Abstract][Full Text] [Related]
37. Intratumour therapy of solid tumours with ricin-antibody conjugates.
Kanellos J; McKenzie IF; Pietersz GA
Immunol Cell Biol; 1989 Apr; 67 ( Pt 2)():89-99. PubMed ID: 2786496
[TBL] [Abstract][Full Text] [Related]
38. Blocking effect of human serum but not of cerebrospinal fluid on ricin A chain immunotoxin potentiation by monensin or carrier protein-monensin conjugates.
Candiani C; Franceschi A; Chignola R; Pasti M; Anselmi C; Benoni G; Tridente G; Colombatti M
Cancer Res; 1992 Feb; 52(3):623-30. PubMed ID: 1732050
[TBL] [Abstract][Full Text] [Related]
39. Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds.
Ramakrishnan S; Bjorn MJ; Houston LL
Cancer Res; 1989 Feb; 49(3):613-7. PubMed ID: 2783383
[TBL] [Abstract][Full Text] [Related]
40. Selective elimination of a B cell subset having acceptor site(s) for T cell-replacing factor (TRF) with biotinylated antibody to the acceptor site(s) and avidin-ricin A-chain conjugate.
Hashimoto N; Takatsu K; Masuho Y; Kishida K; Hara T; Hamaoka T
J Immunol; 1984 Jan; 132(1):129-35. PubMed ID: 6418795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]